Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study

Limited evidence supports the use of early endpoints to evaluate the success of initial treatment of extranodal NK/T-cell lymphoma (ENKTCL) in the modern era. We aim to analyze progression-free survival at 24 months (PFS24) and subsequent overall survival (OS) in a large-scale multicenter cohort of...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yong, Wang, Ying, Liu, Xin, He, Xia, Zhang, Li-Ling, Wu, Gang, Qu, Bao-Lin, Qian, Li-Ting, Hou, Xiao-Rong, Zhang, Fu-Quan, Qiao, Xue-Ying, Wang, Hua, Li, Gao-Feng, Zhu, Yuan, Cao, Jian-Zhong, Wu, Jun-Xin, Wu, Tao, Zhu, Su-Yu, Shi, Mei, Xu, Li-Ming, Su, Hang, Song, Yu-Qin, Zhu, Jun, Zhang, Yu-Jing, Huang, Hui-Qiang, Hu, Chen, Qi, Shu-Nan, Li, Ye-Xiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179849/
https://www.ncbi.nlm.nih.gov/pubmed/32943751
http://dx.doi.org/10.1038/s41375-020-01042-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179849/
https://www.ncbi.nlm.nih.gov/pubmed/32943751
http://dx.doi.org/10.1038/s41375-020-01042-y

Ejemplares similares